Aegerion Pharmaceuticals, Inc.  

(Public, NASDAQ:AEGR)   Watch this stock  
Find more results for AEGR
20.62
0.00 (0.00%)
Real-time:   4:03PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 19.10 - 36.68
Open     -
Vol / Avg. 0.00/634,274.00
Mkt cap 575.01M
P/E     -
Div/yield     -
EPS -1.37
Shares 28.57M
Beta 0.88
Inst. own 120%
Jul 27, 2015
Q2 2015 Aegerion Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 25, 2015
Aegerion Pharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 9:00AM EDT - Add to calendar
Jun 25, 2015
Aegerion Pharmaceuticals Inc Annual Shareholders Meeting - 9:00AM EDT - Add to calendar
May 13, 2015
Aegerion Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 6, 2015
Aegerion Pharmaceuticals Inc at Deutsche Bank Health Care Conference
May 4, 2015
Q1 2015 Aegerion Pharmaceuticals Inc Earnings Call - Webcast
May 4, 2015
Q1 2015 Aegerion Pharmaceuticals Inc Earnings Release
Mar 3, 2015
Aegerion Pharmaceuticals Inc at Cowen Health Care Conference
Feb 26, 2015
Q4 2014 Aegerion Pharmaceuticals Inc Earnings Call - Webcast
Feb 26, 2015
Q4 2014 Aegerion Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -26.65% -24.87%
Operating margin -15.46% -16.86%
EBITD margin - -16.09%
Return on average assets -14.83% -14.07%
Return on average equity -40.52% -28.82%
Employees 295 -
CDP Score - -

Address

1 Main St Ste 800
CAMBRIDGE, MA 02142-1531
United States - Map
+1-617-5007867 (Phone)
+1-617-9457968 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company’s first product, lomitapide, received marketing approval, under the brand name Juxtapid capsules, from the United States Food and Drug Administration as an adjunct to a low-fat diet and other lipid-lowering treatments in adult patients with homozygous familial hypercholesterolemia (HoFH). The Company launched Juxtapid in the United States in January 2013 and received marketing authorization for lomitapide in the European Union, under the brand name Lojuxta hard capsules in July, 2013. Lomitapide is also approved for the treatment of HoFH in Norway, Iceland, Mexico and Canada. It sells lomitapide, on a named patient basis, in Brazil and in a limited number of other countries outside the United States and the European Union where such sales are authorized based on the regulatory approval.

Officers and directors

David I. Scheer Independent Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Marc D. Beer Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
David Aubuchon Interim Chief Financial Officer, Chief Accounting Officer
Bio & Compensation  - Reuters
Craig Fraser Chief Operating Officer,
Age: 50
Bio & Compensation  - Reuters
Anne Marie Cook Senior Vice President, General Counsel, Secretary
Age: 50
Bio & Compensation  - Reuters
William Andrews Senior Vice President - Business Development
Age: 50
Bio & Compensation  - Reuters
Martha Carter Senior Vice President, Chief Regulatory Officer
Age: 62
Bio & Compensation  - Reuters
Mark Sumeray M.D. Chief Medical Officer
Age: 49
Bio & Compensation  - Reuters
Mary Weger Chief Performance Officer
Age: 56
Bio & Compensation  - Reuters
Sol J. Barer Ph.D. Independent Director
Age: 68
Bio & Compensation  - Reuters